Search Results - "Zimarino, Carlo"
-
1
Disruption of CD47-SIRPα signaling restores inflammatory function in tumor-associated myeloid-derived suppressor cells
Published in iScience (19-04-2024)“…Myeloid-derived suppressor cells (MDSCs) are a heterogeneous immune population with diverse immunosuppressive functions in solid tumors. Here, we explored the…”
Get full text
Journal Article -
2
Generation of Fcabs targeting human and murine LAG-3 as building blocks for novel bispecific antibody therapeutics
Published in Methods (San Diego, Calif.) (01-02-2019)“…•Phage display was used to generate Fcabs targeting human and murine LAG-3.•These Fcabs block LAG-3 binding to its target and induce activity in a T cell…”
Get full text
Journal Article -
3
Abstract 5651: A LAG-3/PD-L1 bispecific antibody inhibits tumor growth in two syngeneic colon carcinoma models
Published in Cancer research (Chicago, Ill.) (01-07-2017)“…Combining immunotherapeutic antibodies in cancer treatment has shown benefits over single agents. An alternative to combining two antibodies is the development…”
Get full text
Journal Article -
4
Abstract 2719: Dual blockade of PD-L1 and LAG-3 with FS118, a unique bispecific antibody, induces CD8+ T-cell activation and modulates the tumor microenvironment to promote antitumor immune responses
Published in Cancer research (Chicago, Ill.) (01-07-2018)“…Background Despite advances with therapies targeting the PD-1/PD-L1 pathway, many patients are refractory or relapse following treatment. LAG-3 expression on…”
Get full text
Journal Article -
5
1353 Targeting complement factor H mediated tumor immune and complement evasion as a next generation approach
Published in Journal for immunotherapy of cancer (01-11-2022)“…BackgroundThe complement system plays a crucial part in innate immunity, aiding the destruction of pathogens and removing anomalous cells. Complement Factor H…”
Get full text
Journal Article -
6
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
Published in Journal for immunotherapy of cancer (01-11-2016)“…Adoptive Cellular TherapyO1 IL-15 primes an mTOR-regulated gene-expression program to prolong anti-tumor capacity of human natural killer cellsAndreas…”
Get full text
Journal Article